抗CGRP单克隆抗体的有效性,安全性和对多发性硬化症过程的影响
Viviana Nociti1, Marina Romozzi1, Pietro Annovazzi2
1Dipartimento Universitario di Neuroscienze, Università Cattolica del Sacro Cuore, Rome, Italy; Neurologia, Dipartimento di neuroscienze, Organi di Senso e Torace, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Journal of the neurological sciences
|January 14, 2025
概括
与多发性硬化症 (MS) 疾病修饰疗法 (DMT) 结合抗素基因相关的单克隆抗体 (抗CGRP mAbs) 有效地减少了每月头痛的日子. 这种组合治疗证明了安全性,但没有对MS疾病过程产生负面影响.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
背景情况:
- 偏头痛在患有多发性硬化症 (PwMS) 的人群中很普遍,影响该人口的高达40%.
- 评估与多发性硬化症疾病修饰治疗 (DMT) 相关的抗素基因单克隆抗体 (抗CGRP mAbs) 的联合疗效和安全性至关重要.
研究的目的:
- 在PwMS中评估同步抗CGRP mAb和DMT (mAb和非mAb) 治疗的有效性和安全性.
- 为了确定这种联合治疗对多发性硬化症疾病过程的影响.
主要方法:
- 一项追溯的多中心研究,涉及来自14个中心的25名PwMS,接受了抗CGRP mAbs和稳定的DMT治疗.
- 多发性硬化症结局 (复发,EDSS,MRI活动) 和偏头痛结局 (每月头痛日,止痛药使用) 在治疗前和随访时进行了比较.
- 系统地记录不良事件 (AEs).
主要成果:
- 每月头痛天数 (MHDs) 的显著减少,从22.0降至11.5 (p=0.002).
- 扩展残疾状态量表 (EDSS) 的得分没有显著变化,MRI活动或临床复发的显著增加.
- 治疗中断率低 (24%的抗CGRP mAbs,8%的DMTs) 和轻度不良事件.
结论:
- 与抗CGRP mAbs和DMTs同时进行治疗对于PwMS中偏头痛的管理是安全有效的.
- 这种组合疗法不会对多发性硬化症的病程产生不利影响.
- 抗CGRP mAbs为患有偏头痛的PwMS提供了一个可行的治疗选择.
相关概念视频
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
114
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
114
01:20Myasthenia Gravis: Overview and Treatment
1.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.2K
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
613
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
613
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
206
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
206